<?xml version="1.0" encoding="UTF-8"?>
<p>Antibodies mediating Fc-effector activities were isolated and characterized in numerous studies, which suggest that these antibodies can play a critical role in tumor clearance [
 <xref rid="B25-viruses-12-00276" ref-type="bibr">25</xref>] and immunity to multiple pathogens such as human immunodeficiency virus (HIV) [
 <xref rid="B49-viruses-12-00276" ref-type="bibr">49</xref>,
 <xref rid="B50-viruses-12-00276" ref-type="bibr">50</xref>], Ebola [
 <xref rid="B51-viruses-12-00276" ref-type="bibr">51</xref>], dengue virus (DENV) [
 <xref rid="B52-viruses-12-00276" ref-type="bibr">52</xref>], West Nile virus (WNV) [
 <xref rid="B53-viruses-12-00276" ref-type="bibr">53</xref>] and influenza virus [
 <xref rid="B16-viruses-12-00276" ref-type="bibr">16</xref>,
 <xref rid="B17-viruses-12-00276" ref-type="bibr">17</xref>]. HIV infection remains a health issue on a global scale and vaccine candidates were developed to address this deteriorating issue. Currently, only one HIV vaccine, RV144, shows modest efficacy (31% efficacy) and this efficacy is not associated with neutralizing antibodies but with potent ADCC-Abs [
 <xref rid="B54-viruses-12-00276" ref-type="bibr">54</xref>,
 <xref rid="B55-viruses-12-00276" ref-type="bibr">55</xref>,
 <xref rid="B56-viruses-12-00276" ref-type="bibr">56</xref>,
 <xref rid="B57-viruses-12-00276" ref-type="bibr">57</xref>,
 <xref rid="B58-viruses-12-00276" ref-type="bibr">58</xref>]. 
</p>
